1.
Clin Transl Oncol
; 10(5): 298-9, 2008 May.
Artículo
en Inglés
| MEDLINE
| ID: mdl-18490248
RESUMEN
Rituximab is a treatment option to non-Hodg kin's diffuse large B-cell lymphoma (NHDLBCL) in advanced stage and comorbility. It is known the cardiotoxicity effect of this drug, but there is no previous report describing a complete atrioventricular block (CAVB) secundary to treatment with Rituximab. We present an elderly woman treated with monotherapy with Rituximab who experienced a CAVB after administration of the fifth dose of this drug.